Company profile: Xyall
1.1 - Company Overview
Company description
- Provider of molecular pathology solutions: Tissector HT for high-volume molecular diagnostic labs, integrating with digital pathology and LIMS, dissecting over 80 slides per hour with high accuracy; Tissector TT for small to medium labs, integrating with digital pathology and LIMS, dissecting over 30 slides per hour; and an Annotation Suite for remote viewing, annotation, and case confirmation across any digital pathology file format, integrated with molecular pathology workflow.
Products and services
- Annotation Suite: An interoperable workstation enabling pathologists to view, annotate, and confirm cases remotely, supporting any digital pathology file format and integrated with molecular pathology workflow
- Tissector High Throughput (HT) Solution: An industrial-grade system for high-volume molecular diagnostic labs, integrating with digital pathology and LIMS, dissecting over 80 slides per hour with high accuracy
- Tissector Table Top (TT) Solution: A compact system architected for small to medium molecular pathology labs, integrating with digital pathology and LIMS, dissecting over 30 slides per hour
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Xyall
NanoRepro
HQ: Germany
Website
- Description: Provider of rapid medical self-tests and diagnostics, developing, manufacturing, and distributing products for domestic and clinical use across women's health, fertility, prevention, family planning, health care, allergies, and food intolerance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoRepro company profile →
Anbio
HQ: Germany
Website
- Description: Provider of in vitro diagnostic medical devices and solutions, developing and manufacturing laboratory, at-home, and point-of-care tests for cancer, cardiovascular diseases, infectious diseases, and pharmacogenomics; conducts research and provides diagnosis globally.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anbio company profile →
Diagnostic Medical Systems
HQ: France
Website
- Description: Provider of medical imagery devices dedicated to conventional and digital radiology and bone densitometry, including design, production and marketing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnostic Medical Systems company profile →
Advanced Instruments
HQ: United States
Website
- Description: Provider of scientific and analytical instruments and test kits for biopharmaceutical, clinical, food, dairy, and industrial microbiological markets, including freezing-point osmometers and the Solentim Cell Metric X for cell line development and assurance of clonality. Offers installation, qualification, training, validation, service agreements, and bioprocessing qualification services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advanced Instruments company profile →
CTK Biotech
HQ: United States
Website
- Description: Provider of innovative immunodiagnostic tools and point-of-care diagnostic test kits for the IVD community worldwide, including SARS-CoV-2 rapid antigen, antibody, and real-time PCR tests; a self-administered COVID-19 home antigen test; an OnSite dengue IgG rapid test in the CDC two-step algorithm; and an HIV 1/2 antibody rapid test approved for commercialization in the EU.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CTK Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Xyall
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Xyall
2.2 - Growth funds investing in similar companies to Xyall
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Xyall
4.2 - Public trading comparable groups for Xyall
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →